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VASP: vasodilator-stimulated phosphoprotein 
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Abstract 
During brain development, cAMP induces morphological changes and inhibits growth 
effects in several cell types. However, the molecular mechanisms underlying the growth 
inhibition remain unknown. Tumor suppressor protein phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN) is a lipid phosphatase that inhibits the 
phosphoinositide 3-kinase (PI3K) pathway. The phosphorylation of Akt, which is one of 
the key molecules downstream of PI3K, inhibits apoptosis. In this study, we 
investigated the role of PTEN in cAMP-mediated growth inhibition. 
B92 rat glial cells were treated with 2 different cAMP stimulatory agents, a 
phosphodiesterase (PDE) inhibitor and a -adrenoceptor agonist. Both cAMP 
stimulatory agents induced marked morphological changes in the cells, decreased cell 
number, decreased Akt phosphorylation, activated PTEN, cleaved caspase-3, and 
induced the condensation and fragmentation of nuclei. These results indicate that the 
cAMP stimulatory agents induced apoptosis. Protein phosphatase inhibitor prevented 
cAMP-induced dephosphorylation of PTEN and Akt. In addition, cAMP analogs and 
Epac-selective agonists affected PTEN and Akt activities. 
 4 
These results suggested that cAMP-induced apoptosis may be mediated by 
PTEN activation and Akt inhibition through protein phosphatase in B92 cells. Our 





cAMP stimuli, including the pituitary adenylate cyclase-activating polypeptide, 
can induce morphological changes and astrocytogenesis of rat cortical precursors [23]. 
Therefore, intracellular cAMP seems to play an important role in controlling 
differentiation and proliferation [13, 22]. However, the signaling cascade involved in 
the cAMP-regulated proliferation has not yet been fully elucidated. The tumor 
suppressor protein phosphatase and tensin homolog deleted on chromosome 10 (PTEN) 
has been shown to regulate multiple steps in the development of the central nervous 
system [8, 19]. We hypothesized that PTEN is involved in the regulation of cell 
proliferation by cAMP. PTEN was initially cloned as a tumor suppressor for gliomas [1], 
and it is a phosphoinositide-phosphate phosphatase specific for the 3-position of the 
inositol ring [11]. PTEN and phosphoinositide 3-kinase (PI3K) have opposing effects on 
cellular PI-(3,4,5)-P3 levels and consequently affect cell proliferation, survival, and 
differentiation through various signaling molecules, including Akt. Akt activity is 
negatively regulated by PTEN [3, 18]. Here, we found that increased intracellular cAMP 






Isobutylmethylxanthine (IBMX), isoproterenol (ISO), and Dulbecco’s modified Eagle’s 
medium (DMEM) were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, 
Japan). 8-bromoadenosine-3,5-cyclic monophosphate (8-Br-cAMP) and 
8-(4-chlorophenylthio)-2-O-methyladenosine-3,5-cyclic monophosphate sodium salt 
(8-CPT-cAMP: Epac inhibitor) were obtained from Biaffin GmbH & Co KG (Kassel, 
Germany). H89 and okadaic acid (OA) were obtained from Calbiochem (La Jolla, CA) 
and LC Laboratories (Woburn, MA), respectively. Hoechst 33342 was obtained from 
Molecular Probes (Eugene, OR). Fetal bovine serum (FBS) was obtained from 
Invitrogen Corporation (Carlsbad, CA). Anti-PTEN, anti-phospho-specific PTEN 
(Ser380), anti-phospho-specific Akt (Ser473), anti-cleaved caspase-3, anti--actin, 
horseradish peroxidase (HRP)-linked anti-rabbit IgG, and anti-mouse IgG were 
purchased from Cell Signaling Technology, Inc. (Danvers, MA). Anti-phospho-specific 
 7 
VASP (Ser157) was obtained from Calbiochem (La Jolla, CA). 
 
Cell culture 
B92 rat glioma cells, which were established by Schubert et al. [17], were obtained from 
DS Pharma Biomedical Co., Ltd. (Osaka, Japan), and U87MG human glioblastoma 
cells were provided by Dr. Nakata (Kanazawa University). Both cells were maintained 
in DMEM containing 10% FBS at 37°C in a 5% CO2 incubator. 
 
Count of cell number 
B92 cells and U87MG cells were seeded on 100 mm dishes at a density of 1 × 10
5
 
cells/dish. After 24 hr incubation, the cells in DMEM with serum were treated with 1 
μM IBMX, and/or 1 μM ISO for 72 hr. Cell suspensions were prepared by PBS with 
trypsin, and the number of cells of the suspension was counted. 
 
PTEN and Akt activity assays. 
To determine the effect of cAMP stimulatory agents on PTEN and Akt activities, we 
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investigated the levels of phospho-PTEN and phospho-Akt by various stimulations. 
Increases of the levels of phospho-PTEN and phospho-Akt indicate PTEN-inactivation 
and Akt-activation, respectively. B92 cells and U87MG cells were incubated in DMEM 
with serum for 24 hr, and treated with IBMX (1μM), ISO (1μM), 8-Br-cAMP (1mM) or 
8-CPT-cAMP (5μM) for 10 min with or without H89 (5μM) or OA (1μM). Western 
blotting analyses were performed using the phospho-specific antibodies, phospho-PTEN 
(Ser380) antibody and phospho-Akt (Ser473) antibody. 
 
Western blotting analysis 
Western blotting was performed as described previously [20, 21]. Briefly, proteins were 
extracted from cells, and the protein concentrations were determined using a protein 
assay. Equal amounts of protein were separated by 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The resolved proteins were 
transferred onto polyvinylidene fluoride (PVDF) membranes, which were incubated 
with primary antibodies (1:1000), and then incubated with HRP-linked secondary 
antibodies (1:2000). The blots were developed using the Immobilon Western 
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Chemiluminescence HRP Substrate (Millipore, Billerica, MA). 
 
Electrophysiological experiments 
B92 cells were seeded on 3.5 mm dishes at a density of 1 × 10
3
 cells/dish. After 24 hr 
incubation, the cells in DMEM with serum were treated with 1 μM IBMX, and/or 1 μM 
ISO for 72 hr. Cells were whole-cell voltage clamped using a patch pipette filled with 
an internal solution containing (in mM) 130 K-gluconate, 15 KCl, 10 HEPES, 0.2 
EGTA, 6 MgCl2, 5 Na2ATP, and 0.2 Na2GTP (pH 7.3, adjusted with KOH). The external 
solution contained (in mM) 140 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 
glucose (pH 7.3, adjusted with NaOH). 
 
Morphological assessment of apoptosis 
B92 cells were seeded on 3.5 mm dishes at a density of 1 × 10
3
 cells/dish. After 24 hr 
incubation, the cells in DMEM with serum were treated with 1 μM IBMX, and 1 μM 
ISO for 24 or 72 hr. Cells were stained with Hoechst 33342 (10 g/mL, 15 min). After 
the incubation, the stained cells were observed by fluorescence microscopy, using 
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UV/355 nm excitation and measuring the fluorescence emission of Hoechst 33342 dye 
at 460 nm emission. Under these conditions, Hoechst 33342 stains the nuclei of all cells. 
 
Statistical analysis 
Data are presented as means ± SEM from at least 3 independent experiments. Statistical 
analyses were performed with ANOVA and followed by Dunnett’s test. 
 
Results 
cAMP-stimulating agents promote morphological changes 
We first examined the detailed effects of isobutylmethylxanthine (IBMX), which is a 
phosphodiesterase (PDE) inhibitor, and isoproterenol (ISO), which is a -adrenoceptor 
agonist, on the morphology of B92 cells. 2-adrenoceptors, which are positively 
coupled to adenylate cyclase [10], and IBMX, which inhibits PDE, both increased 
intracellular cAMP levels. cAMP is therefore a prime candidate for the second 
messenger that is involved in the mechanisms changing cell morphology and function. 
Vasodilator-stimulated phosphoprotein (VASP) is a critical factor in regulating actin 
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dynamics, and an increase in phospho-VASP is related to the increased levels of 
intracellular cAMP [4, 10]. Treatment of B92 cells with IBMX and ISO increased 
phospho-VASP protein levels significantly in 10 min and slightly in 72 h compared with 
controls (Fig. 1A). 
Microscopic examination indicated that IBMX and ISO affected the cell 
morphology; cells were extended and spindle-shaped (Fig. 1B). Cell morphology after 
treatment with a combination of IBMX and ISO were markedly changed compared with 
treatment with IBMX alone (Fig. 1B). In the electrophysiological experiments (Fig. 1C), 
an outward current was activated by depolarizing the membrane above -20 mV (300.0  
64.9 pA, n = 10, at +40 mV) in control cells and (452.9  107.2 pA, n = 15, at +40 mV) 
in IBMX-treated cells. Similar depolarizing pulses induced larger outward currents in 
the cells treated with a combination of IBMX and ISO (562.2  97.1 pA, n = 11, at +40 
mV), but there was no sodium inward current, such as that seen in neurons. 
 
cAMP-stimulating agents promote decreases in cell number, tumor suppressor 
protein PTEN activation, Akt deactivation, and cell apoptosis 
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To examine whether decreases in cell number were dependent on cAMP, B92 cells were 
treated with IBMX only or with a combination of IBMX and ISO. IBMX alone and the 
combination of IBMX with ISO decreased cell number (Fig. 2A). The decrease in cell 
number after treatment with IBMX and ISO together was greater than that after 
stimulation with IBMX alone.  
Many reports have suggested that PTEN plays a critical role in brain 
development and cell phenotype changes [7, 14, 15]. In order to further investigate the 
role of PTEN in cAMP-regulated cell growth, we performed western blotting analyses 
using the phospho-specific antibodies, phospho-PTEN (Ser380) antibody and 
phospho-Akt (Ser473) antibody. PTEN phosphorylation of various sites, including 
Ser380, restricted PTEN activity [24]. The dephosphorylation of PTEN also resulted in 
an increase of PTEN activity [24]. The treatment of B92 cells with IBMX alone or with 
IBMX in combination with ISO induced the dephosphorylation of PTEN, which 
indicated an activation of PTEN phosphatase activity (Fig. 2B). This PTEN phosphatase 
activity resulted in an inhibition of Akt activity (Fig. 2B). Therefore, the apoptotic 
enzyme caspase-3 was cleaved (Fig. 2B), and cells with condensed or fragmented nuclei 
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were observed by Hoechst 33342 staining 24 h after treatment with the stimuli (Fig. 2C, 
middle panel), which indicated an induction of apoptosis [9]. However, few cells with 
condensed or fragmented nuclei were observed 72 h after treatment with the stimuli (Fig. 
2C, right panel). 
 
cAMP-induced PTEN activation and Akt deactivation are dependent on protein 
phosphatase and Epac and independent of PKA 
PKA and Epac are molecular players that are downstream of cAMP. Fig. 3A shows the 
effects of PKA inhibition by H89, which blocked the induction of VASP 
phosphorylation by cAMP-stimulating agents, but not the ability of cAMP-stimulating 
agents to dephosphorylate PTEN and Akt. Similarly, H89 failed to block the cAMP 
analog 8-Br-cAMP-induced inhibition of the dephosphorylation of PTEN and Akt (Fig. 
3B, left panel). However, the highly selective Epac agonist 8-CPT-cAMP induced 
PTEN activation and Akt deactivation (Fig. 3C), confirming that Epac, and not PKA, is 
involved in cAMP-dependent PTEN activation and Akt deactivation. Although okadaic 
acid (OA), which is a protein phosphatase inhibitor, increased the level of 
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phosphorylation of PTEN and Akt compared with the control, OA completely abolished 
the ability of cAMP to dephosphorylate PTEN and Akt in Fig 3B (right panel), 
indicating that protein phosphatases might be involved in the cAMP-regulated PTEN 
activity.  
 
PTEN mediates Akt inhibition by cAMP 
PTEN is not expressed in U87MG human glioblastoma cells (Fig. 3D, left panel). 
cAMP-stimulating agents increased phospho-VASP protein levels, but they did not 
inhibit Akt activity (Fig. 3D, middle panel) and cell number (Fig. 3D, right panel) in 
U87MG cells, indicating that the cAMP-induced inhibition of Akt and cell number was 
dependent on PTEN activity. 
 
Discussion 
Our results provide a new insight into the activation of PTEN through protein 
phoaphatase during cAMP-induced apoptosis in B92 cells. The effects of PI3K on Akt 
activation were countered by PTEN, which is a lipid phosphatase of PIP3 [3, 18]. The 
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dephosphorylation of PIP3 by PTEN resulted in the inhibition of Akt activity. In 
response to cAMP stimulation, we observed an increase in the activity of PTEN and a 
decrease in Akt activity in B92 cells that resulted in the induction of apoptosis. An 
inhibitory effect of cAMP on the activation of Akt has been described in various cell 
types [2, 5, 6, 12]. However, the mechanism of cAMP-induced inhibition of Akt is not 
yet fully understood. Specifically, the role of PI3K in cAMP-mediated Akt inhibition is 
still controversial; previous studies have indicated either no effect [5] or negative effects 
[6] of cAMP on PI3K activity. Although PTEN is not a classical target of cAMP action, 
cAMP-dependent PTEN activation has been reported in alveolar macrophages and 
human glioma cells [2, 12]. PKA and Epac are molecular players downstream of cAMP 
[2, 12]. Epac, and not PKA, is involved in cAMP-dependent PTEN activation and Akt 
deactivation [2, 12]. In this study, we showed that PKA is responsible for 
cAMP-dependent VASP phosphorylation, but not cAMP-dependent PTEN activation 
and Akt deactivation (Fig. 3A and 3B). We also suggest that Epac is responsible for 
cAMP-dependent PTEN activation and Akt deactivation (Fig. 3C), confirming that 
cAMP activates PTEN through Epac [2, 12]. Moreover, in this study, it was shown that 
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protein phosphatase plays a key role in cAMP-induced PTEN activation (Fig. 3B). Thus, 
our findings may provide new insight into the mechanistic model by which cAMP 
activates PTEN in glial cells. However, the details regarding the mechanistic 
mechanisms underlying cAMP stimulation of PTEN are still unknown. Further studies 
are required to determine the full mechanism of cAMP-dependent PTEN activation in 
glial cells. 
cAMP has been shown to alter the morphology of primary cortical precursor 
cells and glioma cells [13, 22]. Our results suggested that cAMP acts in B92 cells to 
induce morphological changes within 72 h of the stimuli (Fig. 1B). B92 cells treated 
with cAMP-stimulating agents exhibited outward currents when the membrane was 
depolarized, but not a sodium inward current, like neurons do (Fig. 1C). cAMP 
activated the apoptotic enzyme caspase-3 and increased the number of apoptotic cells 
with fragmented and condensed nuclei (Fig. 2B, 2C). Apoptotic cells were detected 24 h 
after the stimuli, but not 72 h after the stimuli (Fig. 2C). Probably, all of apoptotic cells 
which were detected 24 h after the stimuli might be dead and disappear in 72 h after the 
stimuli, which resulted in the cAMP-induced decrease in cell number (Fig. 2A). From 
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these results, cAMP appears to regulate a number of cell functions, including apoptosis. 
In this study, a decrease in cell number appears concomitant with the 
activation of PTEN by cAMP-stimulating agents in B92 cells (Fig. 2A). It is uncertain 
whether PTEN activation is necessary or sufficient for the regulation of apoptosis and 
cell proliferation. However, cAMP failed to inhibit Akt activation in PTEN-depleted 
U87MG glioblastoma cells (Fig. 3D), and several studies have indicated that PTEN 
regulates multiple steps in the development of the central nervous system, including 
apoptosis [8, 19]. In this study, it appeared that PTEN might play a role in regulating 
apoptosis in response to cAMP stimulation. Further studies are needed to fully elucidate 
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Fig. 1. Changes in the levels of phospho-VASP (A), in the morphology of the cells (B), 
and in the electrophysiological recordings (C) of B92 cells after treatment with IBMX 
(1 M) or a combination of IBMX (1 M) and ISO (1 M). Representative current 
responses to voltage pulses of potentials between -100 mV and +40 mV with a 20 mV 
step from a holding potential of -80 mV (C). 
 
Fig. 2. Changes in cell number (A), in the levels of phospho-PTEN, phospho-Akt, and 
cleaved caspase-3 (B), and in the nuclear morphology (C) of B92 cells after treatment 
with IBMX (1 M) or a combination of IBMX (1 M) and ISO (1 M). Each column 
represents the mean ± SEM. *P < 0.05, **P < 0.01 vs. untreated controls. #P < 0.05 vs. 
IBMX treatment group (A). Several condensed or fragmented apoptotic nuclei are 
indicated by arrows (C). 
 
Fig. 3. Changes in the levels of phospho-PTEN, phospho-Akt, and phospho-VASP in 
B92 cells after treatment with a combination of IBMX (1 M) and ISO (1 M) with or 
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without H89 (5 M) (A), with 8-Br-cAMP (1mM) with or without H89 (5 M) or OA 
(1 M) (B), and with the selective Epac agonist 8-CPT-cAMP (5 M) (C). Changes in 
the levels of phospho-Akt and phospho-VASP, and cell number after treatment of 
PTEN-depleted U87MG glioblastoma cells with a combination of IBMX (1 M) and 
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